At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 405 enrolled
Drug / intervention
RPL554 suspension +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase IIb, Randomized, Double Blind, Placebo Controlled, Dose Ranging Study to Assess the Effect of RPL554 in Patients With Moderate to Severe COPD.
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA·interventional·Posted Feb 23, 2018·Updated Jun 4, 2019
In Brief
A Phase 2 clinical trial evaluating RPL554 suspension and Placebo for COPD. Completed, enrolled 405 participants across 49 sites in 6 countries.
Detailed Summary
The study investigates the effect of 4 weeks of twice daily treatment of four different doses of RPL554 (a phosphodiesterase \[PDE\]3/4 inhibitor) or placebo in patients with moderate to severe chronic obstructive pulmonary disease (COPD). Patients will be equally allocated to one of the five treatment options.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOPD
CountriesBulgaria, Czechia, Germany, Poland, Romania, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartJun 2017
Primary CompletionJan 2018
Study CompletionFeb 2018
First PostedFeb 2018
TodayJul 2026
First PostedFeb 23, 2018
Enrollment StartJun 1, 2017
Primary CompletionJan 23, 2018
Study CompletionFeb 7, 2018
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 8.4 years ago
Interventions
RPL554 suspensiondrug
A dual PDE3/PDE 4 inhibitor
Placebodrug
Placebo solution